Ms Aradhana Rani

PTVL - LAS

DepartmentLiberal Arts and Sciences

Research outputs

Endocrine Resistance in Hormone Receptor Positive Breast Cancer–From Mechanism to Therapy
Rani, A., Stebbing, J., Giamas, G. and Murphy, J.J. 2019. Endocrine Resistance in Hormone Receptor Positive Breast Cancer–From Mechanism to Therapy. Frontiers in endocrinology. 10, p. 245. doi:10.3389/fendo.2019.00245

PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers
Coffey, G., Rani, A., Betz, A., Pak, Y., Haberstock-Debic, H., Pandey, A., Hollenbach, S., Gretler, D.D., Mant, T., Jurcevic, S. and Sinha, U. 2017. PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers. Journal of Clinical Pharmacology . 57 (2), p. 194–210. doi:10.1002/jcph.794

HES1 in immunity and cancer
Rani, A., Greenlaw, R., Smith, R.A. and Galustian, C. 2016. HES1 in immunity and cancer. Cytokine & Growth Factor Reviews. 30, pp. 113-117. doi:10.1016/j.cytogfr.2016.03.010

STAT5 in Cancer and Immunity
Murphy, J.J. and Rani, A. 2016. STAT5 in Cancer and Immunity. Journal of Interferon & Cytokine Research. 36 (4), pp. 226-237. doi:10.1089/jir.2015.0054

The Notch target Hes1, is a STAT5 target gene with implications in cancer
Rani, A., Greenlaw, R., Galustian, C. and Murphy, J.J. 2015. The Notch target Hes1, is a STAT5 target gene with implications in cancer. 2015 Meeting of the ICIS in Bamberg, Germany, October 11th -14th. Bamberg, Germany Oct 2015 doi:10.1016/j.cyto.2015.08.214